Induced Pluripotent Stem Cells Market to Grow with a CAGR of 9.65% through 2028
Rising
increasing use of stem cell therapies is expected to drive the Global Induced
Pluripotent Stem Cells Market growth in the forecast period, 2024-2028.
According
to TechSci Research report, “Induced Pluripotent Stem Cells Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Induced Pluripotent Stem Cells Market stood at USD 1.22
billion in 2022 and is anticipated to grow with a CAGR of 9.65% in the forecast
period, 2024-2028.
One of the
primary drivers propelling the iPSCs market is the rising prevalence of chronic
diseases such as cardiovascular disorders, neurodegenerative conditions,
diabetes, and cancer. These diseases pose a significant global health burden,
and traditional treatment options often fall short of providing long-term cures
or effective therapies. iPSCs offer a ray of hope by enabling the development
of patient-specific treatments, tailored to an individual's unique genetic
makeup. This personalization reduces the risk of immune rejection and enhances
treatment efficacy, making iPSC-based therapies an attractive option for both
patients and healthcare providers. Stem cell therapies are being developed for a variety
of diseases, including heart disease, stroke, diabetes, and Parkinson's
disease. iPSCs can be used to generate the specific cell types needed for these
therapies, which could make them more effective and less likely to be rejected by
the patient's immune system. The biotechnology industry is investing heavily in
iPSC research and development. This is due to the potential of iPSCs to
revolutionize the way we treat diseases. Additionally, Chronic diseases such as
heart disease, cancer, and diabetes are increasing in prevalence. iPSCs could
be used to develop new treatments for these diseases, which could improve the
quality of life for millions of people.
New technologies
are being developed to make it easier and more efficient to produce and use
iPSCs. This is making iPSCs more accessible to researchers and clinicians,
which is driving market growth. The integration of AI and high-throughput
screening techniques is streamlining drug discovery efforts involving iPSCs.
AI-driven algorithms can analyze vast datasets generated from iPSC-based
experiments, identifying potential drug candidates and predicting their effects
on specific diseases. This trend is enhancing the efficiency of drug discovery
pipelines and reducing development costs. Advanced research infrastructure is
crucial for the progress of iPSC research. Academic institutions and research
centers worldwide are investing in state-of-the-art facilities and specialized
equipment for iPSC production and characterization. These facilities are
fostering a conducive environment for cutting-edge research and innovation. The
expansion of research infrastructure is a vital trend supporting iPSCs'
continued development and application. The use of iPSCs for disease modeling has advanced
significantly. Researchers can now generate iPSC-derived models of various
diseases, including rare genetic disorders and infectious diseases. These
models provide valuable insights into disease mechanisms, enabling the
development of more targeted therapies. As iPSC technology continues to evolve,
disease modeling applications are becoming increasingly sophisticated and
relevant.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Induced Pluripotent Stem Cells Market.”
The
iPSCs market is experiencing a surge in investment from both the public and
private sectors. Government grants, venture capital, and pharmaceutical
industry investments are pouring into iPSC research and development. These
financial resources support critical research initiatives, clinical trials, and
the expansion of iPSC-related technologies. The growing interest from investors
underscores the market's potential for long-term growth and innovation.
Governments, research institutions, and biopharmaceutical companies are
recognizing the promise of iPSCs in addressing the healthcare challenges posed
by an aging demographic and are consequently investing in iPSC research,
development, and clinical applications.
The Global
Induced Pluripotent Stem Cells Market is segmented into derived cell type,
application, end user, regional distribution, and company.
Based on
application, the Global Induced Pluripotent Stem Cells Market is segmented into Drug
Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell
Therapy, and Disease Modeling. Based on
the application, the drug development segment emerged as the dominant player in
the global market for Global Induced Pluripotent Stem Cells in 2022. This is on
account of several growing key factors including iPSCs allowing for the
generation of disease-specific cell lines, facilitating the creation of disease
models. This is invaluable for understanding the mechanisms underlying various
diseases, from genetic disorders to complex conditions like Alzheimer's and
Parkinson's disease. Researchers can use these models to study disease
progression and screen potential therapeutic compounds. iPSCs are
particularly valuable for modeling rare diseases, which often have limited
research resources and patient populations. Pharmaceutical companies can use
iPSCs to create disease models for these conditions, leading to the development
of orphan drugs and addressing unmet medical needs.
Based on derived
cell types, the Global Induced Pluripotent Stem Cells Market is segmented into Hepatocytes, Fibroblasts, Keratinocytes, Neurons, and
Others. Based on the Derived Cell Type, the hepatocytes
segment emerged as the dominant player in the global market for Global Induced
Pluripotent Stem Cells in 2022. This is on account of Hepatocytes being a
critical cell type in the iPSCs market, primarily due to their significant role
in liver disease modeling, drug metabolism studies, and drug toxicity testing.
They are essential for understanding how drugs are processed in the liver and
for identifying potential liver-related side effects of pharmaceutical
compounds. Hepatocytes are also used to study liver diseases such as hepatitis
and cirrhosis, making them a valuable asset in drug development and disease
research.
North America
emerged as the dominant player in the global Induced Pluripotent Stem Cells
market in 2022, holding the largest market share. This is on account of several
key factors such as advanced healthcare infrastructure, Strong Research and
Development Ecosystem and high regulatory acceptance. North America boasts a
well-developed healthcare infrastructure, with state-of-the-art hospitals,
clinics, and rehabilitation centers. These facilities are well-equipped to
offer comprehensive lymphedema treatment, including the use of treatment
instruments. The region is a hub for medical research and innovation. Medical
institutions and research centers in North America often lead in the
development of new treatment technologies, including advanced lymphedema
treatment instruments.
Major companies
operating in Global Induced Pluripotent Stem Cells Market are:
- Axol Bioscience Ltd.
- Cynata Therapeutics Limited
- Evotec SE
- Fate Therapeutics, Inc.
- FUJIFILM Cellular Dynamics, Inc.
- Ncardia
- LizarBio Therapeutics (Pluricell
Biotech)
- Reprocell USA, Inc.
- Sumitomo Dainippon Pharma Co., Ltd.
- Takara Bio, Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The global
induced pluripotent stem cells market is being driven by the increasing use of
stem cell therapies, the growing biotechnology industry, and the rising
prevalence of chronic diseases. iPSCs are cells that have been reprogrammed to
an embryonic-like state from adult cells. This makes them a valuable tool for
research and potential therapies, as they can be used to generate any type of
cell in the body. Besides, the increasing use of stem cell therapies is one of
the key drivers of the iPSCs market. Stem cell therapies are being developed
for a variety of diseases, including heart disease, stroke, diabetes, and
Parkinson's disease.
The biotechnology industry is investing heavily in iPSC research and
development, due to the potential of iPSCs to revolutionize the way we treat
diseases. New technologies are being developed to make it easier and more
efficient to produce and use iPSCs. This is making iPSCs more accessible to
researchers and clinicians, which is anticipated to boost market growth. ” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Global
Induced Pluripotent Stem Cells Market -
Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
Segmented By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes,
Neurons, Others), By Application (Drug Development, Regenerative Medicine,
Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling), By End
user (Research Institutions, Other) By Region and Competition”,
has evaluated the future growth potential of Global Induced Pluripotent Stem
Cells Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Induced Pluripotent
Stem Cells Market.
Contact
Mr. Ken Mathews
708 Third
Avenue,
Manhattan, NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com